Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Single dose of NTLA-2002 seen to reduce monthly HAE attacks 95%

Intellia Therapeutics’ experimental gene-editing therapy NTLA-2002 reduced the number of monthly swelling attacks by 95% among 10 people with hereditary angioedema (HAE) treated in the Phase 1 portion of a Phase 1/2 clinical trial, according to newly published data. The single-dose treatment also led to sustained, dose-dependent reductions in…

Takhzyro approved in Europe for HAE patients as young as 2

The European Commission has expanded the approval of Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) as young as 2 years of age. This makes Takhzyro the first routine preventive, or prophylactic, treatment for HAE attacks to be approved for patients younger than 6 in the European…

Disease changes, coexisting conditions impact older patients

Most older adults with hereditary angioedema (HAE) have more frequent and severe swelling attacks, and more chronic diseases that combine to have a negative impact on their quality of life, results from a focus group study show. Other age-related difficulties included financial barriers to accessing medication. Despite these challenges,…

EMA grants PRIME designation to NTLA-2002 gene-editing therapy

The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to Intellia Therapeutics’ NTLA-2002, an experimental gene-editing therapy to prevent swelling attacks in people with hereditary angioedema (HAE). A PRIME designation supports the development of experimental therapies that address unmet medical needs. Eligibility for this status is…

Genetic analysis reveals recurrent HAE with normal C1-INH: Study

A genetic analysis revealed hereditary angioedema (HAE) was hidden among people with chronic, recurring swelling, but without an apparent family history and normal C1-inhibitor (C1-INH) levels, a study reported. Searching for mutations in patients with chronic, recurring angioedema with an inherited component may detect asymptomatic family members at risk…

APeX-P Trial of Orladeyo Now Enrolling Children 2–11 With HAE

Enrollment has begun in APeX-P, a Phase 3 trial designed to evaluate the effects of Orladeyo (berotralstat) in up to 20 children, ages 2–11, with hereditary angioedema (HAE). The open-label study, sponsored by BioCryst Pharmaceuticals, will provide data on Orladeyo’s safety, pharmacological properties, and ability to prevent…

Israel Approves Oral Therapy Orladeyo to Prevent HAE Attacks

Adult and adolescent patients, ages 12 and older, with hereditary angioedema (HAE)  in Israel can now receive once-daily Orladeyo (berotralstat) to prevent HAE-related swelling attacks. The decision to approve the medication by the Israeli Ministry of Health follows similar decisions in Canada and Switzerland, as well as…

High Immune Eosinophil Counts Seen in Rare Case of Angioedema

A Japanese woman was diagnosed with a rare case of non-episodic angioedema associated with eosinophilia (NEAE), with remarkably high levels of immune eosinophil cells in her bloodstream, a recent case report describes. Swelling in her legs and feet, and associated weight gain, were successfully treated with the anti-inflammatory…